¼¼°èÀÇ ¿¬±¸¿ë ´Ü¹éÁú ½ÃÀå
Research-Grade Proteins
»óǰÄÚµå : 1784084
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 180 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,204,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,612,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¿¬±¸¿ë ´Ü¹éÁú ¼¼°è ½ÃÀåÀº 2030³â±îÁö 20¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 10¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¿¬±¸¿ë ´Ü¹éÁú ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 20¾ï ´Þ·¯¿¡ ´ÞÇϰí, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 12.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ »çÀÌÅäÄ«ÀÎ ¹× ¼ºÀåÀÎÀÚ´Â CAGR 13.9%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 6¾ï 8,300¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ç×ü ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 9.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2¾ï 6,570¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 11.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¿¬±¸¿ë ´Ü¹éÁú ½ÃÀåÀº 2024³â¿¡´Â 2¾ï 6,570¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 3¾ï 1,660¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 11.6%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 11.7%¿Í 10.5%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 8.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ¿¬±¸¿ë ´Ü¹éÁú ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

¿¬±¸¿ë ´Ü¹éÁúÀÌ °úÇаú ¹ÙÀÌ¿ÀÀǾàǰÀÇ ¹ßÀü¿¡ ÇʼöÀûÀÎ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

¿¬±¸¿ë ´Ü¹éÁúÀº »ý¸í°øÇÐ, Á¦¾à ¿¬±¸, »ý¸í°úÇп¡¼­ ±âº»ÀûÀÎ ¿ªÇÒÀ» Çϸç, ÀǾàǰ °³¹ß, ºÐÀÚ»ý¹°ÇÐ, Áø´Ü ÀÀ¿ë ºÐ¾ß¿¡¼­ ÁÖ¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ °íµµ·Î Á¤Á¦µÈ ´Ü¹éÁúÀº ´Ü¹éÁúÀÇ ±â´É, »óÈ£ ÀÛ¿ë ¹× ±¸Á¶¸¦ ¿¬±¸Çϱâ À§ÇØ Çмú ¹× »ó¾÷ ¿¬±¸¼Ò¿¡¼­ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á¿Í »ý¹°ÇÐÀû ½Å¾à°³¹ß¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ƯÈ÷ ´Ü¹éÁúüÇÐ, ¼¼Æ÷¹è¾ç ¿¬±¸, È¿¼Ò °áÇÕ ¸é¿ª ÈíÂø ºÐ¼®¹ý(ELISA)¿¡¼­ ¿¬±¸¿ë ´Ü¹éÁú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀçÁ¶ÇÕ ´Ü¹éÁú »ý»ê°ú ´Ü¹éÁú °øÇÐÀÇ ¹ßÀüÀ¸·Î ¿¬±¸ÀÚµéÀº º¸´Ù ¾ÈÁ¤ÀûÀ̰í È®Àå °¡´ÉÇÑ °íǰÁú ´Ü¹éÁúÀ» ½ÇÇè¿¡ »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¹ÙÀÌ¿À Á¦¾à ºÎ¹®ÀÇ Áö¼ÓÀûÀÎ È®Àå°ú ¿¬±¸°³¹ß(R&D)¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡·Î ÀÎÇØ ½Å·ÚÇÒ ¼ö ÀÖ´Â ¿¬±¸¿ë ´Ü¹éÁú ¼Ö·ç¼ÇÀÇ Çʿ伺ÀÌ ´õ¿í Ä¿Áö°í ÀÖ½À´Ï´Ù.

±â¼ú Çõ½ÅÀº ¾î¶»°Ô ¿¬±¸¿ë ´Ü¹éÁú »ý»êÀ» °­È­Çϴ°¡?

ÀçÁ¶ÇÕ DNA ±â¼úÀÇ °³¹ß·Î ¿¬±¸¿ë ´Ü¹éÁúÀÇ »ý»êÀÌ Å©°Ô °³¼±µÇ¾î ¹Ì»ý¹°, Æ÷À¯·ù, °ïÃæÀÇ ¼¼Æ÷°è¿¡¼­ ´Ü¹éÁúÀ» °í¼öÀ²·Î ƯÀÌÀûÀ¸·Î ¹ßÇö ¹× Á¤Á¦ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. CRISPR ±â¹Ý À¯Àüü ÆíÁý ±â¼úÀÇ ÅëÇÕÀº ¶ÇÇÑ ´Ü¹éÁúÀÇ ¹ßÇö°ú ±â´ÉÀ» Çâ»ó½Ã۰í, À¯ÀüÀÚ Á¶Àý°ú ´Ü¹éÁú »óÈ£ÀÛ¿ëÀ» ¿¬±¸ÇÒ ¼ö ÀÖ´Â Á¤¹ÐÇÑ µµ±¸¸¦ ¿¬±¸Àڵ鿡°Ô Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ä£ È­¼º Å©·Î¸¶Åä±×·¡ÇÇ ¹× Áú·® ºÐ¼®¿¡ ±â¹ÝÇÑ Æ¯¼º Æò°¡¿Í °°Àº ´Ü¹éÁú Á¤Á¦ ¹æ¹ýÀÇ ¹ßÀüÀ¸·Î ¿¬±¸¿ë ´Ü¹éÁú Á¦Ç°ÀÇ Àϰü¼º°ú ÀçÇö¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ´Ü¹éÁú ¼³°è¿¡ ÀΰøÁö´É(AI)°ú °è»ê»ý¹°ÇÐÀÌ µµÀԵǸ鼭 ´Ü¹éÁú °øÇÐÀÌ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖÀ¸¸ç, ¾ÈÁ¤¼º°ú Ä¡·á °¡´É¼ºÀ» ³ôÀÎ »õ·Î¿î ´Ü¹éÁú º¯ÀÌü °³¹ßÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀ» ÅëÇØ ¿¬±¸¿ë ´Ü¹éÁúÀº ÃֽаúÇÐ ÀÀ¿ë ºÐ¾ßÀÇ ¾ö°ÝÇÑ Ç°Áú ¹× ¼øµµ ¿ä±¸ »çÇ×À» ÃæÁ·½Ãų ¼ö ÀÖ½À´Ï´Ù.

¾î¶² ½ÃÀå µ¿ÇâÀÌ ¿¬±¸¿ë ´Ü¹éÁú¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁÖµµÇϰí Àִ°¡?

¾à¹° ½ºÅ©¸®´× ¹× ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö¿¡¼­ ´Ü¹éÁú ±â¹Ý ºÐ¼®¹ýÀÇ »ç¿ë Áõ°¡´Â ¿¬±¸¿ë ´Ü¹éÁú¿¡ ´ëÇÑ ¼ö¿ä¸¦ °ßÀÎÇÏ´Â Áß¿äÇÑ ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·áÀÇ È®´ë¿Í ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¿¬±¸¿ë °íǰÁú ´Ü¹éÁú ½Ã¾àÀÇ Çʿ伺ÀÌ ´õ¿í Ä¿Áö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ý¸í°úÇÐ ¿¬±¸½Ç¿¡¼­ÀÇ ÇÏÀ̽º·çDz ½ºÅ©¸®´× ±â¼ú ¹× ÀÚµ¿È­ÀÇ Áõ°¡´Â Ç¥ÁØÈ­µÇ°í ÀçÇö¼ºÀÌ ³ôÀº ´Ü¹éÁú Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. Á¦¾à»ç ¹× CRO(ÀǾàǰ °³¹ß ¼öʱâ°ü)´Â ƯÈ÷ ´ÜŬ·ÐÇ×ü, ÀçÁ¶ÇÕ »ý¹°ÇÐÀû Á¦Á¦ µîÀÇ ½Å¾à ÆÄÀÌÇÁ¶óÀÎÀ» °¡¼ÓÈ­Çϱâ À§ÇØ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸ÂÃãÇü ´Ü¹éÁú ¹ßÇö ¹× Á¤Á¦ ¼­ºñ½ºÀÇ ÀÌ¿ë °¡´É¼ºÀÌ ³ô¾ÆÁö¸é¼­ ¿¬±¸ÀÚµéÀÌ ½ÇÇè¿¡ ÇÊ¿äÇÑ Æ¯¼ö ´Ü¹éÁúÀ» ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾î ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

¿¬±¸¿ë ´Ü¹éÁú ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀº ¹«¾ùÀΰ¡?

¹ÙÀÌ¿ÀÀǾàǰ¿¡ ´ëÇÑ ¿¬±¸°³¹ß ÅõÀÚ Áõ°¡, ´Ü¹éÁú ¹ßÇö ±â¼ú ¹ßÀü, ´Ü¹éÁú ±â¹Ý ºÐ¼®¹ý äÅ÷ü Áõ°¡ µîÀÌ ¼¼°è ¿¬±¸¿ë ´Ü¹éÁú ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ´Ü¹éÁúüÇÐ ¿¬±¸ÀÇ È®´ë¿Í ºÐÀÚ»ý¹°Çп¡¼­ °íǰÁú ´Ü¹éÁú ½Ã¾àÀÇ Çʿ伺ÀÌ ½ÃÀå ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸ÂÃãÀÇ·á¿Í Ç¥Àû Ä¡·áÁ¦ °³¹ßÀÇ ¼ºÀåÀ¸·Î ÀÎÇØ ÀçÁ¶ÇÕ ´Ü¹éÁú ±â¼ú¿¡ ´ëÇÑ ÀÇÁ¸µµ°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. AI¸¦ Ȱ¿ëÇÑ ´Ü¹éÁú °øÇаú ÇÏÀ̽º·çDz ½ºÅ©¸®´× Ç÷§ÆûÀÇ µîÀåÀº ´Ü¹éÁú ¿¬±¸ÀÇ È¿À²¼º°ú È®À强À» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¿¬±¸±â°ü°ú »ý¸í°øÇÐ ±â¾÷µéÀÌ »õ·Î¿î ´Ü¹éÁú ±â¹Ý Ä¡·áÁ¦¿Í Áø´Ü¹ýÀ» Áö¼ÓÀûÀ¸·Î ޱ¸Çϸ鼭, ¿¬±¸¿ë ´Ü¹éÁú¿¡ ´ëÇÑ ¼ö¿ä°¡ È®´ëµÇ¾î ½Å¾à°³¹ß°ú »ý¹°ÀÇÇÐ Çõ½ÅÀÇ ¹Ì·¡¸¦ Çü¼ºÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÎ¹®

Á¦Ç°(»çÀÌÅäÄ«ÀÎ ¹× ¼ºÀåÀÎÀÚ, Ç×ü, ¸é¿ª üũÆ÷ÀÎÆ® ´Ü¹éÁú, ¹ÙÀÌ·¯½º Ç׿ø, È¿¼Ò, ÀçÁ¶ÇÕ Á¦¾î ´Ü¹éÁú, È£¸£¸ó, ±âŸ), ¼÷ÁÖ ¼¼Æ÷(Æ÷À¯·ù ¼¼Æ÷, ¼¼±Õ ¼¼Æ÷, Áø±Õ¡¤È¿¸ð, °ïÃæ ¼¼Æ÷, ±âŸ), ÃÖÁ¾ ¿ëµµ(Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷, Çмú¡¤¿¬±¸±â°ü, ±âŸ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Research-Grade Proteins Market to Reach US$2.0 Billion by 2030

The global market for Research-Grade Proteins estimated at US$1.0 Billion in the year 2024, is expected to reach US$2.0 Billion by 2030, growing at a CAGR of 12.4% over the analysis period 2024-2030. Cytokines & Growth Factors, one of the segments analyzed in the report, is expected to record a 13.9% CAGR and reach US$683.0 Million by the end of the analysis period. Growth in the Antibodies segment is estimated at 9.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$265.7 Million While China is Forecast to Grow at 11.6% CAGR

The Research-Grade Proteins market in the U.S. is estimated at US$265.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$316.6 Million by the year 2030 trailing a CAGR of 11.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.7% and 10.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.9% CAGR.

Global Research-Grade Proteins Market - Key Trends & Drivers Summarized

Why Are Research-Grade Proteins Essential in Scientific and Biopharmaceutical Advancements?

Research-grade proteins play a fundamental role in biotechnology, pharmaceutical research, and life sciences, serving as key components in drug development, molecular biology, and diagnostic applications. These highly purified proteins are used extensively in academic and commercial research labs for studying protein functions, interactions, and structures. The increasing focus on precision medicine and biologic drug discovery has driven demand for research-grade proteins, particularly in proteomics, cell culture studies, and enzyme-linked immunosorbent assays (ELISAs). With the rise of recombinant protein production and advancements in protein engineering, researchers now have access to more stable, scalable, and high-quality proteins for experimental use. The ongoing expansion of the biopharmaceutical sector and growing investments in research and development (R&D) have further propelled the need for reliable, research-grade protein solutions.

How Are Technological Innovations Enhancing Research-Grade Protein Production?

The development of recombinant DNA technology has significantly improved the production of research-grade proteins, enabling scientists to express and purify proteins in microbial, mammalian, and insect cell systems with high yield and specificity. The integration of CRISPR-based genome editing techniques has also enhanced protein expression and functionality, providing researchers with precise tools to study gene regulation and protein interactions. Additionally, advancements in protein purification methods, such as affinity chromatography and mass spectrometry-based characterization, have improved the consistency and reproducibility of research-grade protein products. The adoption of artificial intelligence (AI) and computational biology in protein design is further accelerating protein engineering, allowing for the development of novel protein variants with enhanced stability and therapeutic potential. These innovations are ensuring that research-grade proteins meet the stringent quality and purity requirements of modern scientific applications.

What Market Trends Are Driving the Demand for Research-Grade Proteins?

The increasing use of protein-based assays in drug screening and biomarker discovery has been a significant factor driving the demand for research-grade proteins. The expansion of personalized medicine and the growing interest in cell and gene therapies have further fueled the need for high-quality protein reagents in research. Additionally, the rise of high-throughput screening techniques and automation in life sciences laboratories has created a demand for standardized, reproducible protein products. Pharmaceutical companies and contract research organizations (CROs) are investing heavily in research-grade proteins to accelerate drug discovery pipelines, particularly for monoclonal antibodies and recombinant biologics. The increasing availability of custom protein expression and purification services is also expanding the market, allowing researchers to access specialized proteins tailored to their experimental needs.

What Are the Key Growth Drivers of the Research-Grade Proteins Market?

The growth in the global research-grade proteins market is driven by increasing R&D investments in biopharmaceuticals, advancements in protein expression technologies, and the rising adoption of protein-based analytical methods. The expansion of proteomics research and the need for high-quality protein reagents in molecular biology have further propelled market demand. Additionally, the growth of personalized medicine and targeted drug development has increased the reliance on recombinant protein technologies. The emergence of AI-powered protein engineering and high-throughput screening platforms is enhancing the efficiency and scalability of protein research. As research institutions and biotech companies continue to explore novel protein-based therapeutics and diagnostics, the demand for research-grade proteins is expected to grow, shaping the future of drug discovery and biomedical innovation.

SCOPE OF STUDY:

The report analyzes the Research-Grade Proteins market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Cytokines & Growth Factors, Antibodies, Immune Checkpoint Proteins, Virus Antigens, Enzymes, Recombinant Regulatory Proteins, Hormones, Others); Host Cell (Mammalian Cells, Bacterial Cells, Fungi & Yeast, Insect Cells, Others); End-Use (Pharma & Biotech Companies, Academic & Research Institutes, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â